Praxis Precision Medicines To Highlight Their Epilepsy Portfolio At The International League Against Epilepsy 15th European Epilepsy Congress With Six Presentations
Praxis Precision Medicines To Highlight Their Epilepsy Portfolio At The International League Against Epilepsy 15th European Epilepsy Congress With Six Presentations
praxis precision medicines將在國際抗癲癇聯盟第15屆歐洲癲癇大會上展示其癲癇產品組合，並進行六次演講
Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present preclinical and clinical data from three of its epilepsy programs at the International League Against Epilepsy (ILAE) 15th European Epilepsy Congress (EEC), being held from September 7 to 11, 2024 in Rome, Italy.
praxis precision medicines，一家臨床階段生物製藥公司，將遺傳學見解轉化爲治療中樞神經系統（CNS）紊亂的療法，這些紊亂以神經元興奮-抑制失衡爲特徵。今天宣佈，將在2024年9月7日至11日在意大利羅馬舉行的第15屆國際抗癲癇聯盟（ILAE）歐洲抗癲癇大會（EEC）上，介紹其三個癲癇項目的臨床前和臨床數據。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。